These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 20034137)
21. Update on resistance testing. Van Houtte M J HIV Ther; 2001 Aug; 6(3):61-4. PubMed ID: 11547262 [No Abstract] [Full Text] [Related]
22. Effect of the extent of thiolation and introduction of phosphorothioate internucleotide linkages on the anti-HIV activity of Suligovir [(s4dU)35]. Horváth A; Beck Z; Bardos TJ; Dunn JA; Aradi J Bioorg Med Chem Lett; 2006 Oct; 16(20):5321-3. PubMed ID: 16920358 [TBL] [Abstract][Full Text] [Related]
23. HIV resistance testing benefit is shown. AIDS Alert; 2001 Oct; 16(10):136. PubMed ID: 11590937 [No Abstract] [Full Text] [Related]
24. [Antiretroviral resistance testing. A necessary element in the follow-up of the HIV-infected patient]. Alcamí J; Rubio R Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):1-2. PubMed ID: 11428052 [No Abstract] [Full Text] [Related]
25. HIV resistance testing: a new clinical tool. Jorden VS; Paul SM N J Med; 2000 Oct; 97(10):33-8. PubMed ID: 11064565 [TBL] [Abstract][Full Text] [Related]
26. Viral resistance testing: new data from the XIII International AIDS Conference. Laurence J AIDS Read; 2000 Oct; 10(10):567-8. PubMed ID: 11068789 [No Abstract] [Full Text] [Related]
27. Antiretroviral resistance testing comes of age. Hammer SM; Pedneault L Antivir Ther; 2000 Mar; 5(1):23-6. PubMed ID: 10846589 [No Abstract] [Full Text] [Related]
29. New data brings resistance testing closer to routine clinical use. Murphy MJ Fac Notes (New Orleans La); 1999; 11(3):6. PubMed ID: 11810872 [No Abstract] [Full Text] [Related]
30. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement? Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R; Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650 [TBL] [Abstract][Full Text] [Related]
31. Principles of HIV resistance testing and overview of assay performance characteristics. Richman DD Antivir Ther; 2000 Mar; 5(1):27-31. PubMed ID: 10846590 [TBL] [Abstract][Full Text] [Related]
32. HIV resistance testing proves its value. Proj Inf Perspect; 1999 Sep; (28):14. PubMed ID: 11367356 [TBL] [Abstract][Full Text] [Related]
33. [Drug resistance in antiretroviral therapy of HIV infection]. Oette M; Häussinger D Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670 [TBL] [Abstract][Full Text] [Related]
34. Aryl nucleoside H-phosphonates. Part 15: Synthesis, properties and, anti-HIV activity of aryl nucleoside 5'-alpha-hydroxyphosphonates. Szymańska A; Szymczak M; Boryski J; Stawiński J; Kraszewski A; Collu G; Sanna G; Giliberti G; Loddo R; La Colla P Bioorg Med Chem; 2006 Mar; 14(6):1924-34. PubMed ID: 16290162 [TBL] [Abstract][Full Text] [Related]
37. A physician's primer to antiretroviral drug resistance testing. Wilson JW; Bean P AIDS Read; 2000 Aug; 10(8):469-73, 476-8. PubMed ID: 10967806 [TBL] [Abstract][Full Text] [Related]
38. [Primary resistance to antiretroviral agents]. Soriano V; María Miró J; Guerrero A Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):22-5. PubMed ID: 11428054 [No Abstract] [Full Text] [Related]
39. Companies aim at new HIV targets. Brower V Nat Biotechnol; 1996 Sep; 14(9):1079. PubMed ID: 9669875 [No Abstract] [Full Text] [Related]